Preventative
-
340B, Alzheimer’s, Caught my eye, FDA, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Preventative, Reference Pricing, ValueAMP is WAC — 12/12/25
Read more: AMP is WAC — 12/12/25Much of this week felt like playing catch-up from past weeks. Good timing because rumors are swirling about Most Favored Nation (MFN) demonstration releases for late next week. Comment letter fun during the holidays! For those of you who are new to these parts… welcome! I’m a health policy strategist focused on pharmaceuticals. My goal…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Home Health, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part D, Preventative, Reference Pricing, TariffsAMP is WAC — 12/5/25
Read more: AMP is WAC — 12/5/25It is the kind of month where I walk around with a legal pad to capture all the random thoughts floating around my head. Which is how “figure out gift baking (scones? Levain cookies?)” ends up next to “Look at MedPAC agenda.” There are no dull moments around here. While I’m on the topic. MedPAC…
-
AMP is WAC — 7/18/25
Read more: AMP is WAC — 7/18/25I have a case of existential dread, and yet the world keeps spinning so let’s do this… Caught my Eye More Cowbell. Late last year I put out a report on biosimilars and it called out how the Inflation Reduction Act could hurt innovation and savings for biosimilars. Here is a report from Matrix Global…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Drug shortages, Employers, Inflation Reduction Act, Medicare Negotiation, Medicare Transaction Facilitator, Pharmacy Benefit Managers, Preventative, Reference Pricing
Caught my eye — 5/16/25
Read more: Caught my eye — 5/16/25This week I’ve repeatedly spoken to groups about the President’s Executive Order (EO) on Most Favored Nation (MFN) pricing and I feel a little vulnerable. I am often “authentic” in my explanations. I recognize that to many people I seem biased on a lot of issues but, in my defense, I find most politics maddening…
-
Caught my eye — 5/2/25
Read more: Caught my eye — 5/2/25It has been a week that has rushed by and yet Monday feels like very long time ago. You know these kinds of weeks. So, let’s do a quick roundup of what made me pause between the stimulation overload of Vegas. And So it Begins? The Food and Drug Administration (FDA) has suffered huge staffing…
Latest news
- AMP is WAC — 3/6/26
- AMP is WAC — 02/27/26
- AMP is WAC — 2/20/26
- AMP is WAC — 2/13/26
- AMP is WAC — 2/6/26
Categories
- 340B (62)
- Affordable Care Act (21)
- Alzheimer's (10)
- Biosimilars (31)
- Caught my eye (101)
- Cell and Gene (5)
- Chevron Deference (2)
- CMMI (26)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (55)
- Drug shortages (14)
- DTC (6)
- Employers (20)
- FDA (6)
- Generics (12)
- Health Equity (4)
- Healthcare Costs (39)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (67)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (22)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (76)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (26)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (48)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (30)
- Supply Chain (7)
- Tariffs (1)
- Uncategorized (8)
- Utilization Management (11)
- Vaccines (9)
- Value (18)